Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2017 14:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial

PARIS, May 03, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announced it...
April 27, 2017 12:07 ET | Source: BIOPHYTIS SA

BIOPHYTIS: 2016 Full Year Results

Extension to the USA of the Sarcopenia clinical programConfirmation of the good safety profile of Sarconeos in SARA-PK clinical trialAuthorizations to launch SARA-OBS clinical study, in which...
April 04, 2017 07:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT

Completes €3.7 million private placementArranges a bond financing of €15 million PARIS, April 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in...
March 27, 2017 08:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study

PARIS, March 27, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, announced that the...
March 22, 2017 08:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS to present four scientific studies at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona

PARIS, March 22, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced it will...
March 02, 2017 08:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos’ good pharmacokinetic profile in elderly patients

PARIS, March 02, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today...
November 30, 2016 08:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile

ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
November 22, 2016 07:30 ET | Source: BIOPHYTIS SA

BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients

ROMAINVILLE, France, Nov. 22, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
November 15, 2016 07:30 ET | Source: BIOPHYTIS SA

BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting

ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...
October 24, 2016 07:30 ET | Source: BIOPHYTIS SA

BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B

ROMAINVILLE, France, Oct. 24, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...